123 related articles for article (PubMed ID: 38834151)
1. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Khouri J; Dima D; Li H; Hansen D; Sidana S; Shune L; Anwer F; Sborov D; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Peres L; Hovanky V; Simmons G; Williams L; Raza S; Afrough A; Anderson L; Ferreri C; Hashmi H; Davis J; McGuirk J; Goldsmith S; Borogovac A; Lin Y; Midha S; Nadeem O; Locke FL; Baz R; Hamilton B; Alsina M; Sauter C; Patel K; Kaur G
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38834151
[TBL] [Abstract][Full Text] [Related]
2. Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.
Liu Y; Chen W; Yu M; Li H; Cheng H; Cao J; Yan Z; Shi M; Zhu F; Sun H; Sang W; Li D; Wu Q; Chen C; Zheng J; Xu K; Li Z
Transplant Cell Ther; 2022 Feb; 28(2):118.e1-118.e5. PubMed ID: 34861455
[TBL] [Abstract][Full Text] [Related]
3. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
4. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK
J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248
[TBL] [Abstract][Full Text] [Related]
5. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
6. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
[TBL] [Abstract][Full Text] [Related]
7. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S; Sidana S; Shune L; Puglianini OC; Pasvolsky O; Gonzalez R; Dima D; Afrough A; Kaur G; Davis JA; Herr M; Hashmi H; Forsberg P; Sborov D; Anderson LD; McGuirk JP; Wagner C; Lieberman-Cribbin A; Rossi A; Freeman CL; Locke FL; Richard S; Khouri J; Lin Y; Patel KK; Kumar SK; Hansen DK
J Hematol Oncol; 2024 Jun; 17(1):42. PubMed ID: 38845015
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H; Hansen DK; Peres LC; Puglianini OC; Freeman C; De Avila G; Sidana S; Shune L; Sborov DW; Davis J; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Simmons G; Ferreri C; Kalariya N; Anderson LD; Afrough A; Dima D; Khouri J; McGuirk J; Locke F; Baz R; Patel KK; Alsina M
Haematologica; 2024 May; 109(5):1514-1524. PubMed ID: 37855036
[TBL] [Abstract][Full Text] [Related]
9. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
[TBL] [Abstract][Full Text] [Related]
10. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
12. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Ferment B; Lambert J; Caillot D; Lafon I; Karlin L; Lazareth A; Touzeau C; Leleu X; Moya N; Harel S; Perrot A; Bories P; Vincent L; Lamure S; Mohty M; Malard F; Manier S; Yakoub-Agha I; Schiano De Colella JM; Brisou G; Talbot A; Decaux O; Houot R; Le Gouill S; Bigot N; Facon T; Corre J; Moreau P; Arnulf B;
Br J Haematol; 2024 May; ():. PubMed ID: 38747092
[TBL] [Abstract][Full Text] [Related]
13. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
[TBL] [Abstract][Full Text] [Related]
14. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells.
Lu Y; Zhu H; Liu Y; Wang Y; Sun Y; Cheng H; Yan Z; Cao J; Sang W; Zhu F; Li D; Sun H; Zheng J; Xu K; Li Z
Front Immunol; 2023; 14():1155216. PubMed ID: 37205117
[TBL] [Abstract][Full Text] [Related]
16. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
[TBL] [Abstract][Full Text] [Related]
17. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Minakata D; Ishida T; Ando K; Suzuki R; Tanaka J; Hagiwara S; Ananthakrishnan R; Kuwayama S; Nishio M; Kanda Y; Suzuki K
Int J Hematol; 2023 May; 117(5):729-737. PubMed ID: 36690910
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D; Rashid A; Davis JA; Shune L; Abdallah AO; Li H; DeJarnette S; Khouri J; Williams L; Hashmi H; Raza S; McGuirk J; Anwer F; Ahmed N
Br J Haematol; 2024 Apr; 204(4):1293-1299. PubMed ID: 38263627
[TBL] [Abstract][Full Text] [Related]
20. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
